MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, BRNS had -$40,548K decrease in cash & cash equivalents over the period. -$48,016K in free cash flow.

Cash Flow Overview

Change in Cash
-$40,548K
Free Cash flow
-$48,016K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Effect of exchange rates on cash...
    • Research and development incenti...
    • Depreciation and amortization
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Accrued expenses and other curre...
    • Accounts payable
    • Others

Cash Flow
2025-12-31
Net loss
-66,458
Share based compensation
468
Impairment of long-lived assets
5,794
Impairment of goodwill
0
Depreciation and amortization
5,845
Non-cash lease expenses
3,332
Unrealized foreign exchange loss
-3,742
Change in contingent consideration
26
Non-cash interest expense
51
Deferred tax benefit
-175
Profit on sale of property and equipment
245
Prepaid expenses and other current assets
-1,704
Research and development incentives receivable
-6,417
Accounts payable
-2,202
Accrued expenses and other current liabilities
-3,793
Deferred income
-506
Operating lease liabilities
-1,979
Net cash used in operating activities
-47,979
Proceeds from sale of property and equipment
453
Purchases of property and equipment
37
Net cash provided by/(used) in investing activities
416
Issue of shares from the exercise of stock options
2
Proceeds from issue of ordinary shares, net of issuance costs
0
Net cash provided by financing activities
2
Effect of exchange rates on cash, cash equivalents and restricted cash
7,013
Net decrease in cash, cash equivalents and restricted cash
-40,548
Cash, cash equivalents and restricted cash, beginning of the period
112,400
Cash, cash equivalents and restricted cash, end of the period
71,852
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from sale ofproperty and equipment$453K Issue of shares fromthe exercise of...$2K Effect of exchangerates on cash, cash...$7,013K Net cash providedby/(used) in investing...$416K Net cash provided byfinancing activities$2K Canceled cashflow$37K Net decrease incash, cash...-$40,548K Canceled cashflow$7,431K Research and developmentincentives receivable-$6,417K Depreciation andamortization$5,845K Impairment of long-livedassets$5,794K Unrealized foreignexchange loss-$3,742K Non-cash lease expenses$3,332K Prepaid expenses andother current assets-$1,704K Share basedcompensation$468K Non-cash interestexpense$51K Change in contingentconsideration$26K Purchases of property andequipment$37K Net cash used inoperating activities-$47,979K Canceled cashflow$27,379K Net loss-$66,458K Accrued expenses andother current...-$3,793K Accounts payable-$2,202K Operating leaseliabilities-$1,979K Deferred income-$506K Profit on sale ofproperty and equipment$245K Deferred tax benefit-$175K

Barinthus Biotherapeutics plc. (BRNS)

Barinthus Biotherapeutics plc. (BRNS)